The U.S. Food and Drug Administration late Thursday approved a new kind of drug to treat schizophrenia, a breakthrough after 70 years of incremental innovation that appears to avoid side effects ...
PureTech advanced its KarXT treatment through its own founded entity KarunaTherapeutics, which was acquired by Bristol Myers Squibb in March. Along with a royalty agreement with Royalty Pharma ...